# Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma

> **NCT04067414** · PHASE1 · COMPLETED · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 12 (actual)

## Conditions studied

- Diffuse Large B Cell Lymphoma
- High-grade B-cell Lymphoma
- Transformed Lymphoma
- Primary Mediastinal Large B Cell Lymphoma

## Interventions

- **BIOLOGICAL:** BZ019

## Key facts

- **NCT ID:** NCT04067414
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-08
- **Primary completion:** 2021-06-04
- **Final completion:** 2021-06-04
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2026-02-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04067414

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04067414, "Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04067414. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*